On October 8, Eli Lilly fell 3.34% in regular trading, trading at $1148.86/share, with Turnover of $5.09 billion.

Morgan Stanley and JPMorgan recently raised price targets and positive obesity pipeline data emerged, yet the stock retreated under high-level pressure.

Competition in the weight-loss drug space intensified as Novo Nordisk's CagriSema Phase 3 results showed superior weight loss versus low-dose Zepbound, raising concerns about market share erosion for Eli Lilly's products.

Eli Lilly is a global pharmaceutical leader focused on discovering, developing, manufacturing, and marketing human medicines across roughly 90 countries.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)